Content about Actavis

December 20, 2012
Watson donates medicines to help Hurricane Sandy relief efforts

Actavis has donated $200,000 worth of medicines to help people affected by Hurricane Sandy, a charity organization said Thursday.

STAMFORD, Conn. — Actavis has donated $200,000 worth of medicines to help people affected by Hurricane Sandy, a charity organization said Thursday.

AmeriCares announced that it donated the antibiotics, pediatric medicines and other drugs to healthcare providers helping affected families in New York and New Jersey within days of the storm. Actavis was acquired earlier this year by Watson Pharmaceuticals.

November 29, 2012
NewsBytes — Chain Pharmacy, 12/10/12

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 15, 2012
Shipments of generic version of Bontril PDM begins

Initial shipment of a generic appetite suppressant has started, the drug's manufacturer said Thursday.

NORTHVALE, N.J. — Initial shipment of a generic appetite suppressant has started, the drug's manufacturer said Thursday.

Elite Pharmaceuticals announced the initial shipment of phendimetrazine tartrate tablets in the 35-mg strength, a generic version of Valeant's Bontril PDM, under a manufacturing and supply agreement with Mikah Pharma. Actavis, recently acquired by Watson Pharmaceuticals, will distribute the drug as part of a distribution agreement between Mikah and Actavis.

November 5, 2012
Watson-Actavis latest among generic M&As

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis. Watson announced the $5.6 billion acquisition of Actavis in April, a deal that is expected to make Watson the third-largest generic drug maker in the world, after Teva Pharmaceutical Industries and Mylan.

November 1, 2012
Watson to change brand in 2013

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.

 

October 22, 2012
Watson, Actavis divest more drugs as condition for FTC merger approval

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

NEW YORK – Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

October 16, 2012
FTC approves Watson-Actavis merger

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

PARSIPPANY, N.J. – The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

The unanimous vote in support of the merger follows Watson's agreement to divest a number of marketed and pipeline products to Par Pharmaceutical and Sandoz as a condition to obtaining FTC approval.

October 16, 2012
Par to acquire 14 generics

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

October 10, 2012
FDA approves generic cardiovascular drug

The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

Actavis announced Wednesday the approval of diltiazem hydrochloride extended-release capsules.

The drug is a generic version of Valeant's Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.

October 8, 2012
European Commission approves Watson-Actavis merger

European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

PARSIPPANY, N.J. — European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

Watson said the European Commission had approved its $5.6 billion purchase of the drug maker, formerly based in Iceland, which Watson announced in April 2012.

Watson expects the transaction to be finished by the end of this year, subject to regulatory approval by the Federal Trade Commission. The acquisition is expected to create the world's third-largest generic drug maker.

September 18, 2012
Mergers among generics cos. on the rise

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


July 17, 2012
Watson, Actavis receive second FTC request

Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

PARSIPPANY, N.J. — Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

July 5, 2012
FDA gives tentative approval to generic hypertension drug

Actavis has received a preliminary approval for a generic drug for treating high blood pressure, the drug maker said Thursday.

MORRISTOWN, N.J. — Actavis has received a preliminary approval for a generic drug for treating high blood pressure, the drug maker said Thursday.

June 25, 2012
FDA approves Actavis ADHD drug

The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.

Actavis, whose parent company was recently acquired by Watson Pharmaceuticals, announced the approval of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, also known as mixed-amphetamine salts ER capsules.

May 31, 2012
Actavis launches generic hypertension, chest pain drug

Actavis has launched a generic drug for high blood pressure and chest pain, the company said.

MORRISTOWN, N.J. — Actavis has launched a generic drug for high blood pressure and chest pain, the company said.

Actavis, which recently agreed to an acquisition by Watson Pharmaceuticals, announced the launch of nifedipine extended-release tablets in the 90-mg strength, a generic version of Bayer's Adalat CC.

Various versions of the drug had sales of about $23 million in 2011, according to IMS Health.

May 18, 2012
FDA approves generic Parkinson's disease drug made by Actavis

The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

Actavis, which last month signed a deal with Watson Pharmaceuticals to be acquired for $5.6 billion, announced the approval and launch of ropinirole extended-release tablets in the 2-mg, 4-mg, 6-mg, 8-mg and 12-mg strengths.

The drug is a generic version of GlaxoSmithKline's Requip XL, which had sales of about $59.4 million in 2011, according to IMS Health.

May 16, 2012
ReportersNotebook — Chain Pharmacy, 5/21/12

Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.

SUPPLIER NEWS — Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion. 


May 10, 2012
New office to help integrate Actavis into Watson

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

Watson announced the formation of the global integration management office, which will report directly to president and CEO Paul Bisaro and focus on integrating the Zug, Switzerland-based generic drug maker, which Watson announced it would acquire last month.

April 26, 2012
Watson to buy Actavis for $5.6 billion

Watson has announced its intention to acquire Actavis, the company said.

PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.

Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.

April 24, 2012
Reports: Watson to buy Actavis

Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

NEW YORK — Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

March 21, 2012
Reports: Watson plans to buy Actavis

Watson Pharmaceuticals is looking to acquire Actavis, according to published reports.

NEW YORK — Generic drug maker Watson Pharmaceuticals is looking to acquire Actavis, according to published reports.

News media reported Wednesday that U.S.-based Watson was close to taking over Switzerland-based Actavis for $6.6 to $7.3 billion. Actavis, also a major manufacturer of generic drugs, was formerly based in Iceland and moved its headquarters to Switzerland last year.

February 23, 2012
Mylan's Tony Mauro elected as GPhA chairman

The president of one of the world's largest generic drug manufacturers will serve as chairman of the Generic Pharmaceutical Association, the organization said Thursday.

WASHINGTON — The president of one of the world's largest generic drug manufacturers will serve as chairman of the Generic Pharmaceutical Association, the organization said Thursday.

February 21, 2012
Nearly $1 billion in damages asserted in lawsuit over GERD drug

A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

MUMBAI, India — A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

In a lawsuit filed in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries and Teva Pharmaceutical Industries, Wyeth Pharmaceuticals said it estimated that it suffered damages of $960 million from Sun's and Teva's launches of generic versions of the gastroesophageal reflux disease drug Protonix (pantoprazole).

February 9, 2012
Social media strategist Robin Leedy takes on six new brands

Social media strategist Robin Leedy & Associates, a public relations and social media marketing agency, on Wednesday announced the signing of six clients featuring several brands in the health and beauty space.

MOUNT KISCO, N.Y. — Social media strategist Robin Leedy & Associates, a public relations and social media marketing agency, on Wednesday announced the signing of six clients featuring several brands in the health and beauty space, including FeverAll acetaminophen suppositories by Actavis; Replens by Lil’ Drug Store; SpermCheck Fertility; The Natural Dentist by Revive Personal Products; Redex’s Udderly Smooth; and Boiron USA brands Oscillococcinum, Arnicare and Camilia.

January 30, 2012
Actavis partners with Poland's Bioton to develop insulin products

Iceland-based drug maker Actavis and Poland-based Bioton have formed a partnership that they said would "shake up" the diabetes market.

WARSAW, Poland — Iceland-based drug maker Actavis and Poland-based Bioton have formed a partnership that they said would "shake up" the diabetes market.

Actavis and Bioton announced the signing of a $73.3 million deal to develop, manufacture and commercialize insulin products, including insulin analogues. Of that, Actavis will pay $29.4 million to Bioton when the deal is signed, while the rest will consist of milestone payments.